TABLE 2.
Results for biochemical parameters.
| Serum samples | T1 | T2 | Δ T2 vs. T1 | T3 | Δ T3 vs. T2 | T4 | Δ T4 vs. T2 | p-value, η2 |
|---|---|---|---|---|---|---|---|---|
| MB (ng/mL) | ||||||||
| HBOT | 29.3 ± 7.9 | 92.9 ± 32.4 | +218% | 96.7 ± 36.9 | +4% | 36.3 ± 8.5 | −61% | Group: p = 0.783, η2: 0.004 Time: p < 0.001, η2: 0.459 Interaction: p = 0.591, η2: 0.020 |
| CON | 24.9 ± 5.5 | 137.4 ± 123.2 | +451% | 124.4 ± 102.1 | −9% | 44.9 ± 20.8 | −67% | |
| CK (u/l) | ||||||||
| HBOT | 195.5 ± 86 | 294.2 ± 110.2 | +51% | 378.0 ± 147.0 | +28% | 457.6 ± 194.8 | +55% | Group: p = 0.881, η2: 0.001 Time: p < 0.001, η2: 0.504 Interaction: p = 0.660, η2: 0.013 |
| CON | 210.3 ± 75.9 | 344.8 ± 95.9 | +63% | 526 ± 232.6 | +53% | 635.5 ± 354.5 | +84% | |
| LDH (u/l) | ||||||||
| HBOT | 391.5 ± 59.5 | 480.1 ± 59.2 | +23% | 430.6 ± 85.5 | −12% | 355.5 ± 77.5 | −35% | Group: p = 0.439, η2: 0.034 Time: p < 0.001, η2: 0.568 Interaction: p = 0.484, η2: 0.036 |
| CON | 397.6 ± 41.4 | 517.9 ± 43.8 | +30% | 469.4 ± 142.4 | −9% | 352.9 ± 41.6 | −31% | |
| ALT (u/l) | ||||||||
| HBOT | 16.0 ± 4.7 | 19.1 ± 4.9 | +19% | 18.5 ± 7.3 | −3% | 18.0 ± 5.7 | −6% | Group: p = 0.913, η2: 0.001 Time: p = 0.001, η2: 0.270 Interaction: p = 0.489, η2: 0.042 |
| CON | 16.2 ± 5.2 | 18.8 ± 3.9 | +16% | 17.1 ± 4.4 | −9% | 18.5 ± 5.8 | −2% | |
| AST (u/l) | ||||||||
| HBOT | 25.2 ± 5.9 | 35.2 ± 6.6 | +40% | 33.2 ± 8.2 | −6% | 32.5 ± 12.2 | −8% | Group: p = 0.793, η2: 0.004 Time: p < 0.001, η2: 0.542 Interaction: p = 0.754, η2: 0.011 |
| CON | 23.2 ± 4.6 | 34.8 ± 7.2 | +50% | 32.1 ± 6.6 | −8% | 32.6 ± 10.9 | −6% | |
MB, myoglobin; CK, creatine kinase; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBOT, hyperbaric oxygen therapy group; CON, control group; T1 – pre-match; T2 – post-match; T3 – after HBOT; T4 – 12 h after η2 – partial eta, effect size.